Vaccination coverage

COVER (Cover of Vaccination Evaluated Rapidly)

The COVER programme monitors immunisation coverage data for children in the UK who reach their first, second or fifth birthday during each evaluation quarter.

Vaccination coverage statistics are prepared each quarter from the Northern Ireland Child Health System.

Vaccination coverage for the completed primary vaccination programme is assessed when the child is 12 and 24 months of age. Children are routinely scheduled at 2, 3 and 4 months of age for diphtheria, tetanus, pertussis, polio and haemophilus influenzae type b vaccine (DTaP/IPV/Hib), meningococcal serogroup C conjugate vaccine (MenC) and pneumococal vaccine (PCV).

A booster dose of Hib and MenC vaccine (given as a combined Hib/MenC vaccine) is scheduled at around 12 months, and measles, mumps and rubella (MMR) and PCV booster vaccine at around 13 months.

Children are scheduled to receive preschool (aged 3-5 years), diphtheria, tetanus, pertussis and polio (DTaP/IPV) booster vaccine and second dose MMR vaccine. Therefore, vaccine coverage is also measured at the child's fifth birthday.

Data June 2019

12 months of age.pdf

24 months of age.pdf

5 years of age.pdf

PHE coverage data

HPV Immunisation Programme

In the UK, all 12-13 year old girls are offered HPV vaccination through the national HPV immunisation programme. From September 2008 until August 2012 the programme used the bivalent HPV vaccine (CervarixTM, GlaxoSmithKline) that protects girls against infection with HPV 16 and 18 (associated with over 70% of cervical cancers in the UK). From September 2012, 12-13 year old girls are offered the quadrivalent vaccine (Gardasil, Sanofi Pasteur MSD) which protects against types 16 and 18 and also against types 6 and 11 (associated with the majority of genital warts). From September 2014 the programme will change from a three to a two dose schedule.

Annual HPV vaccination coverage statistics are prepared from the Northern Ireland child Health System. 






PHE HPV data.
HPV data

Pertussis (whooping cough) vaccine in pregnancy programme

In October 2012, the pertussis vaccine in pregnancy programme commenced as an emergency response to a national outbreak. Boostrix-IPV® (which contains diphtheria, tetanus, acellular pertussis and inactivated polio antigens – DTaP/IPV) is now offered from 16 weeks of gestation until delivery.

In August 2017, uptake of pertussis vaccine in pregnancy has been monitored with data extracted from the Northern Ireland Maternity Administrative System (NIMATS), a regional electronic information system that records maternal and neonatal information at delivery.

Monthly and financial year vaccination coverage statistics:

Pertussis (whooping cough) vaccine in pregnancy coverage:

Pertussis vaccine in pregnancy coverage 2017-2019.pdf

Vaccine uptake is calculated as a percentage and = numerator / denominator x 100


  • Numerator = the number of women living in the named Local Commissioning Group (LCG) location at delivery* that received the pertussis vaccine after 16 weeks gestation
  • Denominator = the number of women living in the named Local Commissioning Group (LCG) location at delivery* who delivered in any LCG after 24 weeks gestation (live and still births) during the reporting period

Local Commissioning Group (LCG) location* is the woman’s area of residence which is obtained by mother’s postcode at delivery.

PHE Pertussis vaccine in pregnancy coverage data